The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients

To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients

NCT01301898 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome

NCT02262338 ·Status: COMPLETED ·Phase: PHASE1

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

NCT00630747 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome)

NCT00004454 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

NCT04007536 ·Status: COMPLETED

A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ

NCT05422482 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

NCT04571970 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723

NCT01602601 ·Status: COMPLETED

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

NCT05795361 ·Status: AVAILABLE

A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

NCT04251026 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

NCT05058391 ·Status: COMPLETED ·Phase: PHASE4

Mucopolysaccharidosis Type II Natural History

NCT03529786 ·Status: COMPLETED

RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)

NCT07236606 ·Status: SUSPENDED ·Phase: PHASE3

Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)

NCT01822184 ·Status: COMPLETED

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

NCT05594992 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)

NCT03566043 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

NCT06075537 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3

Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

NCT00069641 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Hunter Outcome Survey (HOS)

NCT03292887 ·Status: COMPLETED

Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®

NCT00937794 ·Status: COMPLETED

Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II

NCT05665166 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Long-term Follow-Up for RGX-121

NCT04597385 ·Status: UNKNOWN

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

NCT05371613 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I

NCT03053089 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Mucopolysaccharidosis Type II Observational

NCT04591834 ·Status: WITHDRAWN